tri-galnac-cooh

Tri-GalNAc-COOH is a ligand for the asialoglycoprotein receptor (ASGPR) commonly employed in Lysosome Targeting Chimera (LYTAC) investigations.

Tri-GalNAc-COOH acetylation represents the acetylated derivative of tri-galactosamine (tri-GalNAc-COOH), utilized in the synthesis of lysosome targeting chimeras (LYTAC).

Tri-GalNAc-PEG3-Azide is a specialized compound designed for lysosomal targeting chimera (LYTAC) research, featuring three asialoglycoprotein receptor (ASGPR) ligands linked by a PEG3 spacer and an azide group for easy conjugation. This compound facilitates efficient internalization into hepatocytes through ASGPR-mediated endocytosis, making it a strategic tool for delivering RNA, Cas9 complexes, or other cargo specifically to liver cells. Additionally, it can be utilized to create LYTACs or to be marked with a dye for tissue imaging applications.

Tri-GalNAc(OAc)3, a triantenerrary N-acetylgalactosamine (tri-GalNAc) ligand, is utilized in the synthesis of GalNAc-lysosome targeting chimeras (LYTAC). These chimeras exploit the asialoglycoprotein receptor to direct protein degradation targets to the lysosome [1].

Tri-GalNAc(OAc)3-Perfluorophenyl is a pentafluorophenyl-modified triantenerrary N-acetylgalactosamine (tri-GalNAc) ligand utilized in the synthesis of GalNAc-lysosome-targeting chimeras (LYTACs). These chimeras facilitate targeted protein degradation through engagement with the asialoglycoprotein receptor [1].

Tri(TLR4-IN-C34-C2-amide-C3-amide-PEG1)-amide-C3-COOH, a chemical compound that serves as a linker incorporating TLR4 inhibitor TLR4-IN-C34, effectively inhibits TLR4 in both enterocytes and macrophages, significantly reducing systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis [1].

Tri-GalNAc-DBCO is a PIP-GalNAc coupling compound that binds ASGPR to drive protein down-regulation and target compounds for protein degradation via copper-free strain-promoted azide-alkyne cycloaddition coupled to azide on a non-specifically labeled antibody.

Tri-GalNAc-NHS ester, a LYsosome TArgeting Chimera (LYTAC) and ligand for the asialoglycoprotein receptor (ASGPR), facilitates the degradation of extracellular proteins, including membrane proteins, via the lysosomal targeting receptor expressed on liver cells. This compound is utilized as a protein degrader in LYTAC research [1].

Tri(TLR4-IN-C34-C2-amide-PEG1)-amide-C3-COOH is a chemical linker with the TLR4 inhibitor TLR4-IN-C34, which inhibits TLR4 in enterocytes and macrophages, reducing systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis [1].

Tri-GalNAc biotin, a small molecule lysosome targeting degrader, serves as a ligand for the asialoglycoprotein receptor (ASGPR). It promotes the uptake of NeutrAvidin (NA) into liver cells via ASGPR and directs NeutrAvidin to the lysosome for degradation. This compound is applicable in the study of Lysosome Targeting Chimeras (LYTAC) [1].

Tri-GalNAc(OAc)3 TFA, a triantenerrary N-acetylgalactosamine (tri-GalNAc) ligand, is utilized in the synthesis of GalNAc-lysosome-targeting chimera (GalNAc-LYTAC). This compound facilitates targeted protein degradation by engaging with the asialoglycoprotein receptor [1].